JGJianbo Gao

Jianbo Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianbo Gao has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Photon-counting CT versus Energy-integrating Detector CT in Imaging Lung Cancer

    by Xiaofei Yang, Mingxin Li, Ke Qi, Kehui Nie, Qianqian Zhao, Xiangnan Li, Songwei Yue, Junqiang Dong, Yonggao Zhang, Zhigang Zhou, et al.

    Compared with energy-integrating detector CT, photon-counting CT with a low radiation dose and reduced contrast agent protocol reduced the incidence of contrast-induced nephropathy and improved diagnostic confidence in patients with lung cancer.


  • Optimization and Initial Diagnostic Performance of Photon-Counting Detector CT for Rectal Cancer T Staging

    by Lina Zhu, Lele Zhang, Zihao Zhao, Kehui Nie, Chenglong Luo, Peijie Lyu, Yonggao Zhang, Jianbo Gao

    In participants with rectal cancer, portal venous abdominal photon-counting detector CT at 40 keV and with quantum iterative reconstruction–4 optimized image quality, potentially enhanced T-staging diagnostic performance, and performed similarly to MRI.


  • Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study

    by Yiyang Liu, Yaru You, Lihong Chen, Jing Li, Mengchen Yuan, Bo Duan, Huiting Ge, Xuejun Chen, Li Yang, Xingzhi Chen, et al.

    Proliferation marker Ki-67 and immune checkpoint Programmed Cell Death Ligand 1 (PD-L1) are both proteins associated with tumor treatment response. To develop and validate two dynamic nomograms from dual-energy CT (DECT) for noninvasive evaluation of the expression status of these two proteins in advanced gastric cancer (AGC), and explore their associations with treatment response. In this multicenter prospective and retrospective study, eligible AGC participants who underwent DECT scans were recruited into two study groups (Ki-67 and PD-L1 groups), with their clinical and DECT characteristics collected and measured. The prediction models (Ki-67 dynamic nomogram (KIDN) and PD-L1 dynamic nomogram (PDDN)) were constructed by logistic regression classifier, respectively, and two online calculators were established based on models. The performance of nomograms was comprehensively evaluated. In total, 459 and 417 eligible patients were analyzed in the Ki-67 and PD-L1 groups, respectively. The nomograms discriminating Ki-67 and PD-L1 achieved AUCs of 0.755 and 0.726, respectively, in the external validation cohort. Additionally, the two nomograms significantly or slightly outperformed any single predictor in both the training and validation cohorts. In both cohorts, KIDN and PDDN showed favorable calibration (Hosmer-Lemeshow test, all p < 0.05) and clinical utility confirmed by decision curve analysis. Moreover, they demonstrated prognostic performance consistent with actual biomarkers and were associated with clinical response to immuno-chemotherapy (both p < 0.05). The dynamic nomograms, which integrate clinical features and DECT quantitative parameters, enable noninvasive evaluation of treatment-related protein expression in AGC. Question Noninvasive tools for accurately evaluating Ki-67 and PD-L1 expression status in advanced gastric cancer (AGC) are currently inadequate. Findings Dual-energy CT-based nomograms demonstrated favorable performance in evaluating Ki-67 and PD-L1 expression status and were associated with response to immuno-chemotherapy in AGC. Clinical relevance We developed online calculators based on prediction models that may serve as a supplement to current invasive methods (e.g., immunohistochemistry), potentially aiding therapeutic decision-making.